Literature DB >> 15047976

Gamma-hydrobutyric acid (GHB) and its chemical modifications: a review of the GHBergic system.

Anna Waszkielewicz1, Jacek Bojarski.   

Abstract

Gamma-hydroxybutyric acid (GHB) is a naturally occurring substance with function of an inhibitory neurotransmitter in the central nervous system in mammals. GHB can be used as a medicine in narcolepsy (Xyrem) and for general anesthesia (sodium oxybate). It is also a popular drug of abuse, causing coma, addiction and severe withdrawal syndrome, and, therefore, demanding thorough studies on the GHBergic system and expanded research on toxicology of this compound. The aim of this review is to present the proved and some suggested mechanisms of its action from pharmacological point of view, which may help to properly treat intoxication or other pathological states caused by GHB ingestion. Some new GHB derivatives studied for analogous action and their present use are also described.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047976

Source DB:  PubMed          Journal:  Pol J Pharmacol        ISSN: 1230-6002


  5 in total

1.  Metabolomic study of polyamines in rat urine following intraperitoneal injection of γ-hydroxybutyric acid.

Authors:  Hyeon-Seong Lee; Chan Seo; Young-A Kim; Meejung Park; Boyeon Choi; Moongi Ji; Sooyeun Lee; Man-Jeong Paik
Journal:  Metabolomics       Date:  2019-04-02       Impact factor: 4.290

2.  An open-label study of sodium oxybate in Spasmodic dysphonia.

Authors:  Anna F Rumbach; Andrew Blitzer; Steven J Frucht; Kristina Simonyan
Journal:  Laryngoscope       Date:  2016-11-03       Impact factor: 3.325

3.  ECOMICS: a web-based toolkit for investigating the biomolecular web in ecosystems using a trans-omics approach.

Authors:  Yoshiyuki Ogata; Eisuke Chikayama; Yusuke Morioka; R Craig Everroad; Amiu Shino; Akihiro Matsushima; Hideaki Haruna; Shigeharu Moriya; Tetsuro Toyoda; Jun Kikuchi
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

4.  Increasing Evidence for the Use of Sodium Oxybate in Multi-Drug-Resistant Lance-Adams Syndrome.

Authors:  Giulietta M Riboldi; Steven J Frucht
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-06-17

5.  A novel therapeutic agent, sodium oxybate, improves dystonic symptoms via reduced network-wide activity.

Authors:  Kristina Simonyan; Steven J Frucht; Andrew Blitzer; Azadeh Hamzehei Sichani; Anna F Rumbach
Journal:  Sci Rep       Date:  2018-10-31       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.